• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Flow Sciences

    Syngene

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Flow Sciences

    PCI Pharma Services

    Baxter BioPharma Solutions

    Cytovance Biologics

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    The Bioprocessing Trek

    Biosimilars are the next speed-bump for CMOs

    The Bioprocessing Trek
    Related CONTENT
    • Asymchem
    • Mogene
    • Softweb Solutions
    • Vetio Animal Health
    • Quality Metrics Feedback
    Emil W. Ciurczak, DoraMaxx Consulting09.16.19
    As larger pharmaceutical companies continue the reciprocal of mergers and acquisitions (M&A), namely divestitures and outsourcing, the pressure is on contract manufacturers to be at least as good as the company that developed the dosage form. That is because product developers are outsourcing production of proprietary products while they are still under patent protection. This means producing not a close imitation to a marketed product, which, I believe, is the definition of generic, but one which is identical, such that there is no difference in content, visual appearance, or performance.

    Making an “equivalent” to an existing small molecule product is difficult enough for a company not involved in its development, but when you include the provisions of the Question-based Review (QbR) Guidance, it becomes more arduous. The QbR for Generic Drugs: An Enhanced Pharmaceutical Quality Assessment System, has as one of its main thrusts requiring ANDAs (Amended New Drug Applications) from disparate companies follow a common form for style. Previously, when each of the large number of generic companies submitted their documents, each used their own internal style. This resulted in reviewers at the U.S. FDA having to navigate dozens of different types of applications, causing long wait times for the generics to get a yes/no answer on their new product’s fate. Imagine an English teacher allowing each student to write a term paper in his/her individual manner. The result would be chaos. This style requirement, alone, made the Guidance an excellent idea and, like a class receiving a term paper assignment, they all understood what was needed and in what order it should be presented. This did, indeed, speed up review times.

    Unfortunately, it also included some responsibilities for the generic company that were new to them. The responsibility for the purity of the product was extended to both earlier and later than had been the case previously. The existing responsibility was to “simply” produce a product, often covered by a monograph in the USP, that met the requirements of purity, assay, disintegration or dissolution times, and so on. Prior to QbR, it was sufficient to depend on the Certificate of Analysis (CoA) for purity, potency, etc. of an active pharmaceutical ingredient (API).

    But, under new Guidances for both FDA and ICH, the generic drug company, including contract manufacturing organizations (CMOs), now needs to ascertain the synthesis route for the API such that they can prove (validate) that their incoming RM testing and stability-indicating assays can identify and quantify any breakdown product from the synthesis of any of API, no matter the synthesis route by which they were produced. This extends to stability programs: each analysis method must be capable of finding and quantifying materials from the breakdown of the dosage form APIs.

    This means a constant feed-back loop between suppliers and the company’s labs, such that any analytical method can separate any and all potential by-products from synthesis and any and all break-down products from stability samples. Now, in a normal or traditional generic company or contract manufacturing facility, there are a number of trained analytical chemists, allowing the methods to morph to the specificity needed. It only adds a small amount of labor and time to the existing workload when small molecules are involved.

    However, when it comes to biological or biosimilar production and sales, all bets are off. Whether the CMO is producing a biological product that was the “original”—under contract to the patent-holder—or generating a product that is “similar,” the process is far more complicated than merely mixing powders and compressing a tablet or encapsulating the mix into a capsule. Understanding the effects of an API on the final dosage form is even covered in ICH Q11:

    “The identification of CQAs (critical quality attributes) for complex products can be challenging. Biotechnological/biological products, for example, typically possess such a large number of quality attributes that it might not be possible to fully evaluate the impact on safety and efficacy of each one. Risk assessments can be performed to rank or prioritize quality attributes. Prior knowledge can be used at the beginning of development and assessments can be iteratively updated with development data (including data from nonclinical and clinical studies) during the lifecycle. Knowledge regarding mechanism of action and biological characterization, such as studies evaluating structure-function relationships, can contribute to the assessment of risk for some product attributes.”

    This control/understanding of biologicals for the companies who have developed the drug is difficult enough, even with a large number of biochemists, molecular biologists, analytical and QC chemists. For smaller companies—both producers of the bioproducts and the generics who package them as dosage forms—largely used to performing small molecule analyses, this makes the task even more difficult. There are two levels of difficulty for a company to prepare to be able to produce and analyze biologically produced medicines:

    1. Previously Characterized Bio-Product
    This would be a biologically-produced drug substance, developed and patented by a major company and contracted to a CMO for production and distribution.
    • Even if all the preliminary analytical and process procedures are worked out by the initiator company, the CMO/generic will need to add analysts familiar with bioassays, purchase new equipment, and such. There will be a relatively small monetary outlay and time to full speed, assuming guidance by the parent company.
    • If the synthesis is done in-house, the facilities need to be expanded and more specialists added to staff. If the API is made by the CMO, all the necessary facilities need to be installed, unless they are already equipped for biosynthesis.
    2. New Synthesis Route for API or “Biosimilar”
    In this case, we still have the needs of analysts and analytical equipment for analyses, hardware and biochemists to make and purify the API, and all the equipment needed for example number one, plus the need to:
    • Isolate any and all byproducts from the expression and determine the effects of each, both short- and long-term, on patients. For example, if a strain of e coli was used to produce the protein. While the major component of the bioreaction may be “identical” to the patented entity, the secondary molecules are likely to be different.
    This will require a level of expertise above merely isolating and following the byproducts from a previously well-researched and characterized API. It will necessitate that the CMO either receives significant technical support from a larger (parent/client) company, or greatly expand its staff and equipment. For example, more stability ovens may be in order, as well as the chromatographs, mass spectrometers, and so forth, which will lead to staff increases to run this additional equipment.
    • Develop stability methodology to follow the major and minor components of the “biosimilar” to be able to track potential toxic effects. This requires considerable analytical development time and effort and would require biological testing of the short- and long-term effects in patients.

    This last point may be the most critical. When a small molecule is synthesized, the initial chemicals, in-process materials, and potential by-products are relatively simple to elucidate. This makes assay methods and evaluation of the results relatively straightforward. There are tests for carcinogenicity and mutagenicity available, and have been for decades, for small molecules. There are commonly used parameters for limits on breakdown products and impurities (USP, for example) for easily identified chemicals.

    With biological impurities, often proteins not seen previously, the stakes are potentially higher. Not only are there potential carcinogenicity and mutagenicity dangers, but, with unknown proteins, there are also potential immediate allergic reactions. Assuming there are no immediate reactions, there are potential long-term potential harmful effects, depending on the therapy for which the biological is being used. If the drug is a one-time application, such as heparin, there would not likely be a chance for the minor impurities to do much harm. On the other hand, long-term use of a bio-drug such as insulin, often used for decades, would allow even the smallest impurity the time to do harm to the patient.

    One might assume that a company that develops an NDE (new drug entity), based on a bioprocess, will spend years assessing potential harmful effects. A biosimilar would have, by definition, less time for any potential side-products to be evaluated before marketing. While the major active may be identical to the patented one, any biological process expresses numerous proteins, each particular to the mode of expression. When all is said and done—excluding potential lawsuits for patent-infringement, etc.—the most problematic feature of any biosimilar will be the exotic side products and potential side-effects.

    Considering the benefits to patients both therapeutic and financial, I truly wish that biosimilars can be produced safely. In any case, when contract manufacturers and/or generic companies embark on the bioprocessing trek, they will need to staff up with some experienced biochemists and such and do some bio-testing, if not their own clinical studies. But, in the end, the work is worth it.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • it
    • Dosage
    • fda
    • Stability
    Suggested For You
    Asymchem Asymchem
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Quality Metrics Feedback Quality Metrics Feedback
    FDA Extends CRADA with CluePoints FDA Extends CRADA with CluePoints
    Roche Wins Two Approvals for Cancer Drug Rozlytrek Roche Wins Two Approvals for Cancer Drug Rozlytrek
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing
    Merck to Build $650M Biomanufacturing Plant in NC Merck to Build $650M Biomanufacturing Plant in NC
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    06	Merck 06 Merck
    Re-Open Your Tool Chest Re-Open Your Tool Chest
    Syndax Pharma Gets IND Clearance for Leukemia Treatment Syndax Pharma Gets IND Clearance for Leukemia Treatment
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    Sierra’s Momelotinib Granted FDA Fast Track Designation Sierra’s Momelotinib Granted FDA Fast Track Designation

    Related Columns

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17

    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17


    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16

    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16


    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15

    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15


    • Biosimilars | Fill/Finish | QA/QC

      CMOs Are Willing to Pay for More Innovation

      Downstream improvements top the list
      Eric S. Langer, BioPlan Associates 09.11.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15

    • Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      Biosimilars and Their Future in Medicine

      The first step is understanding what biosimilars actually are
      Ben Locwin, Healthcare Science Advisors 06.02.15


    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    • APIs | Biosimilars | Process Development | Supply Chain

      Biosimilars Improving Efficiency, Cost for All Biologics

      ...
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.01.15

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login